Valuation Macro Group Pharmaceuticals (Macro Capital) S.A.E

Stocks

End-of-day quote Egyptian Exchange 03/09/2026			5-day change	1st Jan Change
1.530 ^EGP	+2.68%		+2.00%	+34.21%

05-17	Macro Group Pharmaceutical Q1 consol profit egp 33.3 million	RE
02-19	Macro Group Pharmaceuticals (Macro Capital) S.A.E Reports Earnings Results for the Full Year Ended December 31, 2025	CI

Data adjusted to current consolidation scope

Fiscal Period: December	2025	2026	2027	2028
Market Cap ¹	650	872.4	-	-
Change	-	34.21%	-	-
Enterprise Value (EV) ¹	650	792.7	762.4	604.4
Change	-	21.95%	-3.82%	-20.72%
P/E	5.7x	25.5x	17x	13.9x
PBR	-	9x	6.95x	5.67x
PEG	-	-0.4x	0.3x	0.6x
Capitalization / Revenue	-	0.73x	0.56x	0.45x
EV / Revenue	-	0.67x	0.49x	0.31x
EV / EBITDA	-	2.93x	2x	1.2x
EV / EBIT	-	3.3x	2.26x	1.36x
EV / FCF	-	16.8x	4.26x	1.75x
FCF Yield	-	5.94%	23.5%	57.2%
Dividend per Share ²	-	0.03	0.04	0.06
Rate of return	-	1.96%	2.61%	3.92%
EPS ²	0.2	0.06	0.09	0.11
Distribution rate	-	50%	44.4%	54.5%
Net sales ¹	-	1,190	1,552	1,946
EBITDA ¹	-	271	381	504
EBIT ¹	-	240	337	444
Net income ¹	115.7	206	283	373
Net Debt ¹	-	-79.7	-110	-268
Reference price ²	1.140	1.530	1.530	1.530
Nbr of stocks (in thousands)	570,206	570,206	-	-
Announcement Date	19/02/26	-	-	-

¹EGP in Million²EGP

Estimates

Add to a list 0 selected To use this feature you must be a member Log in Sign up	P/E (N)	EV / Sales (N)	EV / EBITDA (N)	Dividend Yield (N)	Capi.($)
MACRO GROUP PHARMACEUTICALS (MACRO CAPITAL) S.A.E	25.5x	0.67x	2.93x	-	17.12M
ELI LILLY AND COMPANY	32.72x	11.9x	24.26x	0.6%	1,024B
JOHNSON & JOHNSON	30.62x	-	-	1.95%	663B
ABBVIE INC.	32.73x	7.6x	15.8x	2.67%	453B
ROCHE HOLDING AG	19.89x	4.73x	11.71x	2.8%	352B
NOVARTIS AG	22.72x	5.84x	14.51x	2.7%	304B
ASTRAZENECA PLC	20.87x	4.29x	12.24x	2.06%	252B
AMGEN INC.	27.66x	7.14x	13.15x	2.31%	236B
NOVO NORDISK A/S	13.33x	4.82x	10.06x	3.78%	206B
GILEAD SCIENCES, INC.	-46.14x	6.65x	25.95x	2.18%	187B
Average	17.99x	5.96x	14.51x	2.34%	367.84B
Weighted average by Cap.	24.05x	7.99x	17.80x	1.95%